Opinion|Videos|October 28, 2024
Luspatercept Role in the RS-Negative Population and Expert Perspectives on the Role of EPO Levels
Panelists discuss how luspatercept’s role in ring sideroblast–negative MDS populations is evolving based on recent clinical trial data, including the COMMANDS trial and PACE-MDS study, with particular attention to the impact ofEPO levels on treatment decisions and outcomes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of luspatercept in the RS-negative population? When do you consider it as first-line treatment in this particular patient population?
Resource link: COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024).
Resource link: Platzbecker U, et al. Phase II PACE-MDS study. J Clin Oncol, 2022.
Resource link: Platzbecker U, et al. Comparative biomarkers by RS status COMMANDS trial. EHA 2024, abstract P763.
- How do EPO levels factor into your treatment approach for this patient
- Please comment on outcomes in the COMMANDS trial (Della Porta MG, et al. Lancet Haematol, 2024) based on EPO levels (<200).
Advertisement
Related to this article
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Tycel Phillips, MD, discusses sonrotoclax’s FDA approval for mantle cell lymphoma and why the BCL2 inhibitor opens more possibilities.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
The OncFive: Top Oncology Articles for the Week of 8/30
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know
5